Business Context and Reporting Period
Company: MyMD Pharmaceuticals, Inc. (MYMD)
Filing Type: Form 8-K (Current Report)
Date of Report: May 20, 2024
Reporting Period: Immediate event reporting regarding capital raising activities.
MyMD Pharmaceuticals, Inc. entered into two material definitive agreements on May 20, 2024, to raise capital through private placements of convertible preferred stock and warrants. The transactions are exempt from registration under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D.
Key Financial Metrics and Capital Structure
Expected Gross Proceeds:
- Series G Private Placement: $8.9 million
- Series F-1 Private Placement: $5.0 million
- Total Expected Proceeds: $13.9 million
Use of Proceeds: General corporate purposes.
Placement Agent Fees: 3% cash fee of gross proceeds plus 3% of underlying shares issued as warrants.
Security Details:
- Series G Preferred Stock: 8,950 shares; Stated value $1,000/share; Conversion price $1.816/share; 10% annual dividend (compounded monthly, payable in cash or stock); 15% dividend rate upon Triggering Event.
- Series F-1 Preferred Stock: 5,050 shares; Stated value $1,000/share; Conversion price $1.816/share; 10% annual dividend; Mandatory redemption in 8 equal monthly installments starting October 1, 2024.
- Warrants: Short-term (18-month expiry) and Long-term (5-year expiry) warrants issued for both series with an exercise price of $1.816/share.
Financial Performance Metrics: The filing text does not provide revenue, profit, cash flow, or margin data for the current or prior periods.
Material Changes and Agreements
Private Placements: The Company agreed to sell Series G and Series F-1 Convertible Preferred Stock and associated warrants to accredited investors. Closing is expected on or around May 22, 2024.
Series F Modifications: The Company entered into an Omnibus Waiver, Consent, Notice and Amendment with Series F Holders to:
- Extend the maturity date of Series F Preferred Stock to December 31, 2024.
- Modify installment payment procedures for July and August 2024.
- Waive certain rights regarding the issuance of new Preferred Stock and the reservation of shares until stockholder approval is obtained.
Conversion Price Adjustments: Due to the new private placements at $1.816/share, the conversion and exercise prices of the existing Series F Preferred Stock and Series F Warrants were automatically reset to $1.816.
Guidance, Outlook, and Risks
Stockholder Approval Requirement: The Company must hold a stockholder meeting no later than August 1, 2024, to approve:
- Issuance of common stock exceeding 19.99% of outstanding shares at prices below the Nasdaq "Minimum Price."
- Increase in authorized shares to meet reserve requirements.
Registration Rights: The Company must file resale registration statements for 200% of the conversion shares and warrant shares within 30 days of closing. Failure to do so for Series F-1 may result in liquidated damages.
Risks and Contingencies:
- Triggering Events: Failure to pay amounts due may trigger a 15% dividend rate and allow holders to demand cash redemption at a premium.
- Dilution: Significant dilution is expected upon conversion of preferred stock and exercise of warrants, subject to beneficial ownership limitations.
- Liquidity: No established public trading market exists for the new preferred stock or warrants.
Investor Verification Checklist
- Verify the closing date and actual proceeds received (expected ~May 22, 2024).
- Confirm the scheduling and outcome of the stockholder meeting required by August 1, 2024.
- Monitor the filing and effectiveness of the resale registration statements (due within 30 days of closing).
- Review the impact of the $1.816 conversion price reset on existing Series F holders.
- Assess the Company's ability to meet the mandatory monthly redemption installments for Series F-1 starting October 1, 2024.